Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome

Richard D. Hurt, Troy D. Wolter, Nancy Rigotti, J. Taylor Hays, Raymond Niaura, Michael J. Durcan, David Gonzales, David P.L. Sachs, J. Andrew Johnston, Kenneth P. Offord

Research output: Contribution to journalArticle

Abstract

The aim of this study was to identify predictors of successful relapse prevention in smokers receiving long-term sustained-release bupropion. Smokers (N=784) who were interested in stopping smoking were enrolled in a 7-week, open-label bupropion phase. Abstinent subjects at the end of treatment and eligible to proceed (N=429) were randomized to active bupropion or placebo through Week 52 and then followed for an additional year. The best overall predictor of less relapse to smoking was assignment to active bupropion. In aggregate, the results indicate that bupropion can be prescribed to diverse populations of smokers with expected comparable results. There was a medication effect that was independent of any predictor except older age and those who gained no or minimal weight during the open-label phase. Predictors of successful relapse prevention included lower baseline smoking rates, a Fagerström Tolerance Questionnaire score of <6, and initiation of smoking at an older age. These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies.

Original languageEnglish (US)
Pages (from-to)493-507
Number of pages15
JournalAddictive Behaviors
Volume27
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Bupropion
Secondary Prevention
Smoking
Labels
Drug therapy
Placebos
Weights and Measures
Recurrence
Drug Therapy
Population

Keywords

  • Bupropion
  • Nicotine dependence
  • Relapse prevention
  • Smoking

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Toxicology
  • Psychiatry and Mental health

Cite this

Hurt, R. D., Wolter, T. D., Rigotti, N., Hays, J. T., Niaura, R., Durcan, M. J., ... Offord, K. P. (2002). Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome. Addictive Behaviors, 27(4), 493-507. https://doi.org/10.1016/S0306-4603(01)00188-5

Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome. / Hurt, Richard D.; Wolter, Troy D.; Rigotti, Nancy; Hays, J. Taylor; Niaura, Raymond; Durcan, Michael J.; Gonzales, David; Sachs, David P.L.; Johnston, J. Andrew; Offord, Kenneth P.

In: Addictive Behaviors, Vol. 27, No. 4, 2002, p. 493-507.

Research output: Contribution to journalArticle

Hurt, RD, Wolter, TD, Rigotti, N, Hays, JT, Niaura, R, Durcan, MJ, Gonzales, D, Sachs, DPL, Johnston, JA & Offord, KP 2002, 'Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome', Addictive Behaviors, vol. 27, no. 4, pp. 493-507. https://doi.org/10.1016/S0306-4603(01)00188-5
Hurt, Richard D. ; Wolter, Troy D. ; Rigotti, Nancy ; Hays, J. Taylor ; Niaura, Raymond ; Durcan, Michael J. ; Gonzales, David ; Sachs, David P.L. ; Johnston, J. Andrew ; Offord, Kenneth P. / Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome. In: Addictive Behaviors. 2002 ; Vol. 27, No. 4. pp. 493-507.
@article{5e48f66fec66405b9568b1548eb06a39,
title = "Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome",
abstract = "The aim of this study was to identify predictors of successful relapse prevention in smokers receiving long-term sustained-release bupropion. Smokers (N=784) who were interested in stopping smoking were enrolled in a 7-week, open-label bupropion phase. Abstinent subjects at the end of treatment and eligible to proceed (N=429) were randomized to active bupropion or placebo through Week 52 and then followed for an additional year. The best overall predictor of less relapse to smoking was assignment to active bupropion. In aggregate, the results indicate that bupropion can be prescribed to diverse populations of smokers with expected comparable results. There was a medication effect that was independent of any predictor except older age and those who gained no or minimal weight during the open-label phase. Predictors of successful relapse prevention included lower baseline smoking rates, a Fagerstr{\"o}m Tolerance Questionnaire score of <6, and initiation of smoking at an older age. These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies.",
keywords = "Bupropion, Nicotine dependence, Relapse prevention, Smoking",
author = "Hurt, {Richard D.} and Wolter, {Troy D.} and Nancy Rigotti and Hays, {J. Taylor} and Raymond Niaura and Durcan, {Michael J.} and David Gonzales and Sachs, {David P.L.} and Johnston, {J. Andrew} and Offord, {Kenneth P.}",
year = "2002",
doi = "10.1016/S0306-4603(01)00188-5",
language = "English (US)",
volume = "27",
pages = "493--507",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Bupropion for pharmacologic relapse prevention to smoking - Predictors of outcome

AU - Hurt, Richard D.

AU - Wolter, Troy D.

AU - Rigotti, Nancy

AU - Hays, J. Taylor

AU - Niaura, Raymond

AU - Durcan, Michael J.

AU - Gonzales, David

AU - Sachs, David P.L.

AU - Johnston, J. Andrew

AU - Offord, Kenneth P.

PY - 2002

Y1 - 2002

N2 - The aim of this study was to identify predictors of successful relapse prevention in smokers receiving long-term sustained-release bupropion. Smokers (N=784) who were interested in stopping smoking were enrolled in a 7-week, open-label bupropion phase. Abstinent subjects at the end of treatment and eligible to proceed (N=429) were randomized to active bupropion or placebo through Week 52 and then followed for an additional year. The best overall predictor of less relapse to smoking was assignment to active bupropion. In aggregate, the results indicate that bupropion can be prescribed to diverse populations of smokers with expected comparable results. There was a medication effect that was independent of any predictor except older age and those who gained no or minimal weight during the open-label phase. Predictors of successful relapse prevention included lower baseline smoking rates, a Fagerström Tolerance Questionnaire score of <6, and initiation of smoking at an older age. These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies.

AB - The aim of this study was to identify predictors of successful relapse prevention in smokers receiving long-term sustained-release bupropion. Smokers (N=784) who were interested in stopping smoking were enrolled in a 7-week, open-label bupropion phase. Abstinent subjects at the end of treatment and eligible to proceed (N=429) were randomized to active bupropion or placebo through Week 52 and then followed for an additional year. The best overall predictor of less relapse to smoking was assignment to active bupropion. In aggregate, the results indicate that bupropion can be prescribed to diverse populations of smokers with expected comparable results. There was a medication effect that was independent of any predictor except older age and those who gained no or minimal weight during the open-label phase. Predictors of successful relapse prevention included lower baseline smoking rates, a Fagerström Tolerance Questionnaire score of <6, and initiation of smoking at an older age. These data should encourage others to perform similar pharmacologic relapse prevention studies with this or other pharmacotherapies.

KW - Bupropion

KW - Nicotine dependence

KW - Relapse prevention

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=0036318613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036318613&partnerID=8YFLogxK

U2 - 10.1016/S0306-4603(01)00188-5

DO - 10.1016/S0306-4603(01)00188-5

M3 - Article

VL - 27

SP - 493

EP - 507

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

IS - 4

ER -